Compare ALTI & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALTI | ZURA |
|---|---|---|
| Founded | 2020 | 2022 |
| Country | United States | United States |
| Employees | 490 | 40 |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.5M | 455.4M |
| IPO Year | 2021 | N/A |
| Metric | ALTI | ZURA |
|---|---|---|
| Price | $3.62 | $5.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 274.5K | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $254,956,000.00 | N/A |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $10.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.75 | $1.26 |
| 52 Week High | $5.45 | $7.25 |
| Indicator | ALTI | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 56.97 |
| Support Level | $3.27 | $4.22 |
| Resistance Level | $3.93 | $5.88 |
| Average True Range (ATR) | 0.25 | 0.55 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 61.54 | 65.09 |
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.